阿霉素载药微球与传统的碘化油经导管动脉化疗栓塞术治疗原发性肝癌疗效的Meta分析

目的比较阿霉素载药微球TACE(DEB-TACE)与传统的碘化油TACE(cTACE)治疗原发性肝细胞癌(HCC)的近期疗效。方法计算机检索中国期刊全文数据库、中国生物医学文献数据库、中文科技期刊全文数据库、PubMed、CochraneLibrary、EMBASE,检索日期为2000年12月—2013年6月有关DEB-TACE与cTACE治疗HCC的随机对照试验(RCT)文献,依据Jadad评价手册评价文献质量。根据纳入和排除标准筛选文献。对纳入文献提取原始数据,采用RevManManager 5.1软件进行Meta分析,计算合并OR值及95%可信区间(95%CI)。结果最终纳入8篇文献,共885例患者。Meta分析结果显示:完全缓解OR:1.67,95%CI(1.21,2.31),P=0.10];部分缓解OR:1.16,95%CI(0.85,1.60),P=0.90];病变稳定OR:0.70,95%CI(0.45,1.07),P=0.17];6个月生存率OR:1.62,95%CI(0.82,3.21),P=0.96];12个月生存率OR:1.65,95%CI(1.04,2.61),P=0.74]。结论 DEB-TACE与cTACE对于治疗HCC的近期疗效差异无统计学意义,但能提高1年生存期。

Meta-analysis of comparative study between doxoruibcin-eluting beads and conventional transarterial hemoembolization for hepatocellular carcinoma

Objective To compare the short-term effect of the Doxorubicin-eluting Beads chemoembolization (DEB-TACE) with the conventional TACE (cTACE) in hepatocellular carcinoma (HCC). Methods PubMed, Medline, Embase, the Chinese BioMedical Literature and the China Nationl Knowledge Infrastructure were searched for randomized controlled trails comparing DEB-TACE and cTACE for treatment of HCC from December 2000 to June 2013. Meta-analysis was performed using RevMan Manager 5.1 software from the Jadad collaboration. Pooled odds ratios (ORs) with 95%CIs were calculated. Results Totally 8 randomized controlled trials comprising 885 patients treated by cTACE versus DEB-TACE for HCC were enrolled. Meta analysis showed that: Complete response OR: 1.67, 95%CI 1.21, 2.31], P=0.10]; partial response OR: 1.16, 95%CI 0.85, 1.60], P=0.90]; stable disease OR: 0.70, 95%CI 0.45, 1.07], P=0.17]; Median overall survival (Mos) of 6 months OR:1.62, 95%CI 0.82, 3.21], P=0.96]; Mos of 12 months OR:1.65, 95%CI 1.04, 2.61], P=0.74]. Conclution Compared to cTACE, the short-term efficacy of DEB-TACE has no difference, but can provide a higher 1-year survival rate.